THE GENERIC INDUSTRY OFFERS PHENOMENAL OPPORTUNITIES, AND A SUBSTANTIAL RISK

Built on more than a decade’s experience supplying solutions to meet critical business challenges in the highly competitive and global generic and API markets, Newport products are now used by more than 250 companies operating in 50 countries around the world.

If you are an API manufacturer, we can help you target products for development, uncover buyers for your active ingredients, monitor your competition, and find partners. Read more about Newport Premium (for Generics).

To submit information about products you currently have in production or under development and your manufacturing capabilities, kindly please complete the online form or email your completed PDF to the Newport manufacturing capabilities team.

If you are a generic company, we can help you target products for development, locate qualified sources of API, monitor your competition, and find partners. Read more about Newport Premium (for Generics).

If you are an innovator, we can help you monitor your competition, find licensing partners, and locate sources of API. Read more about Newport Premium (for Innovators).

If you are specialty company, we can help you target products for development, locate qualified sources of API, monitor your competition, and find partners and licensing opportunities.  Read more about Newport Premium (for Innovators).

If you are a PBM, health insurer, or retail pharmacy, we can help you manage your costs by enabling you to identify likely suppliers and their relative negotiating strengths, intensity of competition, and timing of generic entry. Read more about Newport Premium (for Generics).

If you are a financial company, we can help you monitor generic competition for key products and companies. Read more about Newport Premium (for Generics).

Our solutions for Generics, API Manufacturers, PBMs, Pharmacies, and Analysts
  • Newport Premium (for Generics): The critical product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market.
  • Newport Phase III Drugs Module PDF Intelligence on products still in phase III clinical trials or going through registrations.
  • Newport Generic Deals Module PDF Thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.
  • Newport US Market Share Module PDF The Newport US Market Share Module covers 10 years of product market share history that can be analyzed by dose form, strength, manufacturer, and brand vs. generic. This module integrates seamlessly with Newport Global or Newport Premium base systems, considerably enhancing the visibility of industry dynamics and insight into the U.S. pharmaceutical market. Request more information on the Newport US Market Share Module
  • Newport Biologics Module PDF The Newport Biologics Module contains unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing biosimilar opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature references. Also included is U.S. BLA (Biologics License Application) data for drugs approved through this regulatory route. This module integrates seamlessly with Newport Premium base system. Request more information on the Newport Biologics Module
Our solutions for Innovators
  • Newport Premium (for Innovators): The most advanced competitive intelligence, business development, and global API sourcing system from Thomson Reuters.
  • Newport Generic Deals Module PDF Thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.
  • Newport US Market Share Module PDF The Newport US Market Share Module covers 10 years of product market share history that can be analyzed by dose form, strength, manufacturer, and brand vs. generic. This module integrates seamlessly with Newport Global or Newport Premium base systems, considerably enhancing the visibility of industry dynamics and insight into the U.S. pharmaceutical market. Request more information on the Newport US Market Share Module
  • Newport Biologics Module PDF The Newport Biologics Module contains unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing biosimilar opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature references. Also included is U.S. BLA (Biologics License Application) data for drugs approved through this regulatory route. This module integrates seamlessly with Newport Premium base system. Request more information on the Newport Biologics Module

MORE FROM NEWPORT